EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells
Author:
Funder
Associazione Italiana Ricerca sul Cancro
Publisher
Elsevier BV
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference68 articles.
1. Signatures of mutational processes in human cancer;Alexandrov;Nature,2013
2. DTIC (NSC-45388) in malignant melanoma: a perspective;Comis;Cancer Treat Rep,1976
3. Management of cutaneous melanoma;Tsao;N Engl J Med,2004
4. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993;Atkins;J Clin Oncol,1999
5. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy;Rosenberg;Clin Cancer Res,2011
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs;Pharmaceuticals;2023-10-09
2. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU);Frontiers in Immunology;2022-12-14
3. RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1;Frontiers in Pharmacology;2022-09-20
4. Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2022-07
5. Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives;Cancers;2022-05-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3